5908-62-3,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5908-62-3,1,1-Dioxo-isothiazolidine,as a common compound, the synthetic route is as follows.
A flask was charged under nitrogen with 3-bromo-5-iodo-benzoic acid tert-butyl ester D8b (1 g, 2.6 mmol, 1 equiv), Cs2CO3 (1.26 g, 3.9 mmol, 1.5 equiv), tris (DIBENZYLIDENEACETONE) DIPALLADIUM (0) (12 mg, 0.013 mmol, 0.005 equiv), Xantphos (22 mg, 0.038 mmol, 0.015 equiv) and toluene (20 ML). ISOTHIAZOLIDINE 1,1-dioxide (D22a) (350 mg, 2.9 mmol, 1.1 equiv) was then added and the resulting mixture was stirred at 100C for 16 h then cooled to room temperature and diluted with AcOEt. The organic phase was washed with saturated aqueous NAHC03 solution, dried over MGS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3-BROMO-5-(1, 1-DIOXO-116-ISOTHIAZOLIDIN-2-YL)-BENZOIC acid tert-butyl ester (D17) (350 mg 38%) as a white solid.
As the paragraph descriping shows that 5908-62-3 is playing an increasingly important role.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2004/50619; (2004); A1;,
Thiazolidine – Wikipedia
Thiazolidine – ScienceDirect.com